169 related articles for article (PubMed ID: 29507674)
21. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined
Sachpekidis C; Goldschmidt H; Kopka K; Kopp-Schneider A; Dimitrakopoulou-Strauss A
EJNMMI Res; 2018 Apr; 8(1):28. PubMed ID: 29633046
[TBL] [Abstract][Full Text] [Related]
22. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
23. Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma.
Thomas E; Mathieu C; Moreno-Gaona P; Mittelheisser V; Lux F; Tillement O; Pivot X; Ghoroghchian PP; Detappe A
Adv Healthc Mater; 2022 Jan; 11(2):e2101565. PubMed ID: 34710281
[TBL] [Abstract][Full Text] [Related]
24. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
25. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
26. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
28. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.
Rousseau C; Ruellan AL; Bernardeau K; Kraeber-Bodéré F; Gouard S; Loussouarn D; Saï-Maurel C; Faivre-Chauvet A; Wijdenes J; Barbet J; Gaschet J; Chérel M; Davodeau F
EJNMMI Res; 2011 Sep; 1(1):20. PubMed ID: 22214534
[TBL] [Abstract][Full Text] [Related]
29. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
30. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.
Persson M; Hosseini M; Madsen J; Jørgensen TJ; Jensen KJ; Kjaer A; Ploug M
Theranostics; 2013; 3(9):618-32. PubMed ID: 24052804
[TBL] [Abstract][Full Text] [Related]
31. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
32. Targeting VPAC1 Receptors for Imaging Glioblastoma.
Tripathi SK; Kean R; Bongiorno E; Hooper DC; Jin YY; Wickstrom E; McCue PA; Thakur ML
Mol Imaging Biol; 2020 Apr; 22(2):293-302. PubMed ID: 31292914
[TBL] [Abstract][Full Text] [Related]
33. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
34.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
35. [
Valtorta S; Toscani D; Chiu M; Sartori A; Coliva A; Brevi A; Taurino G; Grioni M; Ruffini L; Vacondio F; Zanardi F; Bellone M; Moresco RM; Bussolati O; Giuliani N
Front Oncol; 2021; 11():760732. PubMed ID: 34712616
[TBL] [Abstract][Full Text] [Related]
36. 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.
Sai KK; Huang C; Yuan L; Zhou D; Piwnica-Worms D; Garbow JR; Engelbach JA; Mach RH; Rich KM; McConathy J
J Nucl Med; 2013 Jul; 54(7):1120-6. PubMed ID: 23650628
[TBL] [Abstract][Full Text] [Related]
37. Successful Application of CuAAC Click Reaction in Constructing
Lee W; Sarkar S; Pal R; Kim JY; Park H; Huynh PT; Bhise A; Bobba KN; Kim KI; Ha YS; Soni N; Kim W; Lee K; Jung JM; Rajkumar S; Lee KC; Yoo J
ACS Appl Bio Mater; 2021 Mar; 4(3):2544-2557. PubMed ID: 35014372
[TBL] [Abstract][Full Text] [Related]
38. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.
Cai H; Wu JS; Muzik O; Hsieh JT; Lee RJ; Peng F
J Nucl Med; 2014 Apr; 55(4):622-8. PubMed ID: 24639459
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
40. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
